References
- Perna G , SchruersK , AlciatiA , CaldirolaD . Novel investigational therapeutics for panic disorder . Expert Opin. Investig. Drugs24 ( 4 ), 491 – 505 ( 2015 ).
- Aoki A , IshiguroS , WatanabeTet al. Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder . Neuropsychiatr. Dis. Treat.10 , 1793 – 1798 ( 2014 ).
- Fabbri C , Di GirolamoG , SerrettiA . Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research . Am. J. Med. Genet. B. Neuropsychiatr. Genet.162B ( 6 ), 487 – 520 ( 2013 ).
- Fabbri C , MinariniA , NiitsuT , SerrettiA . Understanding the pharmacogenetics of selective serotonin reuptake inhibitors . Expert Opin. Drug Metab. Toxicol.10 ( 8 ), 1093 – 1118 ( 2014 ).
- Hamilton SP . The promise of psychiatric pharmacogenomics . Biol. Psychiatry77 ( 1 ), 29 – 35 ( 2015 ).
- Strug LJ , SureshR , FyerAJet al. Panic disorder is associated with the serotonin transporter gene (slc6a4) but not the promoter region (5-httlpr) . Mol. Psychiatry15 ( 2 ), 166 – 176 ( 2010 ).
- Unschuld PG , IsingM , ErhardtAet al. Polymorphisms in the serotonin receptor gene htr2a are associated with quantitative traits in panic disorder . Am. J. Med. Genet. B. Neuropsychiatr. Genet.144B ( 4 ), 424 – 429 ( 2007 ).
- Lonsdorf TB , RuckC , BergstromJet al. The symptomatic profile of panic disorder is shaped by the 5-httlpr polymorphism . Prog. Neuropsychopharmacol. Biol. Psychiatry33 ( 8 ), 1479 – 1483 ( 2009 ).
- Perna G , FavaronE , Di BellaD , BussiR , BellodiL . Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene . Neuropsychopharmacology30 ( 12 ), 2230 – 2235 ( 2005 ).
- Saeki Y , WatanabeT , UedaMet al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in japanese patients with panic disorder . Eur. J. Clin. Pharmacol.65 ( 7 ), 685 – 691 ( 2009 ).
- Ishiguro S , WatanabeT , UedaMet al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder . Eur. J. Clin. Pharmacol.67 ( 12 ), 1213 – 1221 ( 2011 ).
- Kim W , ChoiYH , YoonKS , ChoDY , PaeCU , WooJM . Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the korean population . Prog. Neuropsychopharmacol. Biol. Psychiatry30 ( 8 ), 1413 – 1418 ( 2006 ).
- Yevtushenko OO , OrosMM , ReynoldsGP . Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-ht1a receptor gene polymorphism . J. Affect. Disord.123 ( 1–3 ), 308 – 311 ( 2010 ).
- Favaron E , BiffiS , GrassiM , BellodiL , PernaG . Response to paroxetine and catecol-o-metil transferasi (comt) polymorphisms in panic disorder . Presented at : 11th National Congress of the Italian Society of Pyschopathology . Rome, Italy , March 2006 .
- Woo JM , YoonKS , ChoiYH , OhKS , LeeYS , YuBH . The association between panic disorder and the l/l genotype of catechol-o-methyltransferase . J. Psychiatr. Res.38 ( 4 ), 365 – 370 ( 2004 ).
- Schumacher J , KristensenAS , WendlandJR , NothenMM , MorsO , McMahonFJ . The genetics of panic disorder . J. Med. Genet.48 ( 6 ), 361 – 368 ( 2011 ).
- Fabbri C , PorcelliS , SerrettiA . From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment . Can. J. Psychiatry59 ( 2 ), 62 – 75 ( 2014 ).
- Narasimhan S , LohoffFW . Pharmacogenetics of antidepressant drugs: current clinical practice and future directions . Pharmacogenomics13 ( 4 ), 441 – 464 ( 2012 ).
- Reynolds GP , McgowanOO , DaltonCF . Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms . Br. J. Clin. Pharmacol.77 ( 4 ), 654 – 672 ( 2014 ).
- Perna G , AlciatiA , PrestiaD , TortiT , NemeroffCB . Is there a link between child abuse and neglect ans anxiety disorders?Minerva Psichiatrica54 ( 2 ), 137 – 148 ( 2013 ).